AzTrials
AzTrials

Endometrial CancerDOSTCONICGNCT07380698

The Effect of Dose and Storage Conditions of Indocyanine Green on Efficacy and Cost in Sentinel Lymph Node Mapping in Gynecological Cancer

An observational study of Endometrial Cancer and Vulvar Cancers, run by Cukurova University at 1 site in Turkey (Türkiye).

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This research will determine the impact of optimizing dosage and storage conditions for indocyanine green on health outcomes and will contribute to improving treatment processes in gynecological cancers. Ultrastaging will increase the detection of micrometastases. Read more about this study

Who is it for?
Any age, women only
How many people
30 participants
Where
1 siteTurkey (Türkiye)
Study dates
3 Oct 2025to 3 Sep 2026
How long will I take part?
1 Month
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • Women only
  • No healthy volunteers
  • Child, Adult, Older adult

Study population: Women who have endometrial or cervical or vulvar cancer

Who may be able to join

  • cervical cancer, endometrial cancer, vulvar cancer, using indocyanine green, sentinel lymph node dissection

Who cannot join

  • -

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Ghanim Khatib, MD contact

+903223386060

ghanim.khatib@gmail.com

Turkey (Türkiye)1 site, 1 recruiting
  • Cukurova University

    Adana, 01000

    ghanim khatib, MD, +903223386060, ghanim.khatib@gmail.com

    Recruiting

Other trials in Turkey (Türkiye)

About this study

This research will determine the impact of optimizing dosage and storage conditions for indocyanine green on health outcomes and will contribute to improving treatment processes in gynecological cancers. Ultrastaging will increase the detection of micrometastases. Furthermore, the cost impact of these optimizations will be evaluated. It will help develop more effective, safe, and cost-effective methods for sentinel lymph node mapping in gynecological cancers. Furthermore, significant savings in healthcare costs could be achieved.

Read the detailed description

Indocyanine Green (ICG) is a substance used in many areas of medicine, particularly in surgical procedures for vascular imaging, organ function assessment, and the treatment of various types of cancer. In recent years, this substance has also gained significant ground in gynecological cancers. The use of indocyanine green in gynecological cancers is particularly notable for its role in identifying cancer cells, performing lymph node biopsies, and performing minimally invasive surgeries.

Indocyanine green has become an important tool in the treatment of gynecological cancers, particularly in lymph node biopsies and minimally invasive surgeries. Its applications are increasingly expanding as it helps identify the path of cancer spread and enhances surgical precision. This substance allows surgeons to perform more accurate and effective interventions while also accelerating patient recovery.

Sentinel lymph node (SLN) mapping is increasingly used in gynecologic cancers as a less morbid staging method, an alternative to systematic pelvic and para-aortic lymphadenectomy. Numerous prospective studies have demonstrated the accuracy and reliability of the SLN technique, particularly in endometrial, cervical, and vulvar cancers. Indocyanine green (ICG), when used in conjunction with near-infrared fluorescence imaging, has become the most frequently used method due to its high sensitivity and bilateral detection rate.Patients diagnosed with endometrial, cervical, and vulvar cancer and scheduled for SLN mapping will be included in the study; potential confounding variables such as patient characteristics (age, BMI, comorbidities), tumor characteristics (histology, stage), surgical approach, and surgeon experience will also be considered in the analyses. Indocyanine green administration in gynecological cancers:

  1. Standard dose (1.25 mg/mL, 4 x 1 mL)
  2. A low-volume protocol (1 mL) may be tried in low-risk cases for minimal intervention, but signal may be reduced.
  3. A high-volume application (8-10 mL) may be preferred in obese or signal-deficient patients; signal strength may be increased.
  4. A high concentration (2.5 mg/mL) has been found effective in some studies, but should be used with caution due to the risk of suppressing ICG's own fluorescence.

Standard storage conditions:

Storage at 2-8°C (refrigerated) in dark glass vials protected from light and moisture.

Short-term storage at room temperature (15-25°C) after preparation is suitable. Use within 24 hours is recommended. In this study, sentinel lymph node mapping will be performed by injecting 1 cc of indocyanine green diluted with sterile water (25 mg + 20 mL water → 1.25 mg/mL) into the submucosa of the cervical os at the 3-9 o'clock positions.

Prepared ICGs will be stored in a dark environment at +4°C.

The data obtained will evaluate the effects of the dosage on mapping success and also reveal the potential effects of indocyanine green storage conditions on efficacy and cost. This study aims to contribute to the development of a safer, more effective, and more economical mapping method for gynecological cancers.

Parameters used in this study:

  • Age (years)
  • BMI (kg/m²)
  • Parity
  • Comorbidities (DM, HT, cardiac/AKI, COPD, renal failure)
  • Drug/allergy history (especially iodine/ICG/green dye)
  • Previous pelvic surgery/lymph node dissection/RT-CT history
  • ASA score
  • Cancer type: endometrium, cervix, vulva
  • Cancer stage (clinical and/or pathological)
  • Histology (endometrioid/serous/clearcell/squamous, etc.)
  • Tumor size (mm), depth of myometrial invasion (%) in endometrial cancers, LVSI (present/absent), depth of stromal invasion in cervical tumors, parametrial involvement, lesion location and size in the vulva
  • Need for reinjection: Present/Absent
  • Injection sites and plan: 3-9 line (superficial/deep) on the cervix, clitoris level on the vulva, labia majora; cervical injection standardization for the endometrium. -Storage conditions
  • Freshly prepared vs. stored for a certain period
  • Temperature: Room temperature vs. Refrigerator
  • Operative: Laparoscopic/Laparotomic
  • Operative duration (min), time to SLN (min)
  • Intraoperative complications (allergic reaction, tissue staining problems, etc.)
  • Number of lymph nodes: Total SLNs removed, SLNs per side
  • Anatomical distribution: Obturator, external/internal iliac, parametrial, presacral, etc.
  • Micro/macrometastasis, isolated tumor cells
Keywords
endometrial cancer, vulvar cancers, cervical cancers
Medical subject headings
Endometrial Neoplasms, Vulvar Neoplasms, Uterine Cervical Neoplasms

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sentinel lymph node detection success rate associated with optimized indocyanine green (ICG) dosage and storage conditions.

    Measured: Baseline (pre-procedure), perioperative/periprocedural period, and up to 24 weeks post-procedure.

Secondary outcomes (1)
  1. Impact of optimizing indocyanine green (ICG) dosage and storage conditions on total procedural cost.

    Measured: Baseline (pre-procedure) and up to 24 weeks post-procedure.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Feb 2026
  2. Study start3 Oct 2025
  3. Primary completion3 Aug 2026 (estimated)
  4. Study completion3 Sep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
30 participants (estimated)
Target duration
1 Month
IDs, dates and publications
ClinicalTrials.gov ID
NCT07380698
Sponsor's protocol ID
159/24
Acronym
DOSTCONICG
Status last verified
Jan 2026
First submitted
1 Jan 2026
Last updated
2 Feb 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes

Publications

  • Bedynska M, Szewczyk G, Klepacka T, Sachadel K, Maciejewski T, Szukiewicz D, Fijalkowska A. Sentinel lymph node mapping using indocyanine green in patients with uterine and cervical neoplasms: restrictions of the method. Arch Gynecol Obstet. 2019 May;299(5):1373-1384. doi: 10.1007/s00404-019-05063-6. Epub 2019 Feb 14.

    PubMed 30762108
  • Laufer J, Scasso S, Papadia A. Impact of Indocyanine Green Dose on Sentinel Lymph Node Mapping in Cervical Cancer: A Systematic Review. Cancers (Basel). 2024 Sep 8;16(17):3107. doi: 10.3390/cancers16173107.

    PubMed 39272965
  • Cibula D, Potter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C, Kohler C, Landoni F, Lax S, Lindegaard JC, Mahantshetty U, Mathevet P, McCluggage WG, McCormack M, Naik R, Nout R, Pignata S, Ponce J, Querleu D, Raspagliesi F, Rodolakis A, Tamussino K, Wimberger P, Raspollini MR. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. Int J Gynecol Cancer. 2018 May;28(4):641-655. doi: 10.1097/IGC.0000000000001216.

    PubMed 29688967
  • Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Chu C, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Holmes J, Howitt BE, Lea J, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian NR, Aggarwal S. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Feb;21(2):181-209. doi: 10.6004/jnccn.2023.0006.

    PubMed 36791750

Questions about this trial

What is this clinical trial studying?

An observational study of Endometrial Cancer and Vulvar Cancers, run by Cukurova University at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Ghanim Khatib, MD (+903223386060, ghanim.khatib@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sentinel lymph node detection success rate associated with optimized indocyanine green (ICG) dosage and storage conditions. (time frame: Baseline (pre-procedure), perioperative/periprocedural period, and up to 24 weeks post-procedure.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07380698, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in